John Luo

Long acting injection versus oral risperidone in first-episode schizophrenia: Differential impact on white matter myelination trajectory

Erika P. Raven, G. Bartzokis, K. Nuechterlein, 2011, Schizophrenia Research.

Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia

Erika P. Raven, G. Bartzokis, K. Nuechterlein, 2012, Schizophrenia Research.

A randomized controlled trial of cognitive remediation and long-acting injectable risperidone after a first episode of schizophrenia: improving cognition and work/school functioning

K. Nuechterlein, M. Bell, J. Ventura, 2020, Psychological Medicine.

Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.

K. Nuechterlein, S. Marder, G. Hellemann, 2015, JAMA psychiatry.

The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophrenia

K. Nuechterlein, G. Hellemann, J. Ventura, 2014, Schizophrenia Research.

Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.

K. Nuechterlein, S. Marder, G. Hellemann, 2015, JAMA psychiatry.